Bandaram Pharma Packtech has scheduled its Annual General Meeting for Thursday, September 24, 2026, to transact business including the adoption of financial statements for FY26. The meeting was initially planned for September 18 but was postponed due to certain circumstances. Shareholders will vote on ordinary and special resolutions via video conferencing.

Financial Performance

On a standalone basis, the company reported a net loss of ₹116.05 lakh for FY26, a significant deterioration from the net profit of ₹14.00 lakh in the previous year. Revenue from operations declined 10.4% to ₹1,095.99 lakh from ₹1,222.83 lakh. Total expenses remained relatively flat at ₹1,212.63 lakh compared to ₹1,213.12 lakh in FY25.

Consolidated results showed a different trajectory. Group revenue surged 70.2% to ₹6,292.32 lakh from ₹3,696.37 lakh. However, consolidated net profit fell 71.7% to ₹28.12 lakh from ₹99.38 lakh. The divergence between standalone losses and consolidated profits highlights the contribution of subsidiaries, particularly VSR Paper and Packaging Limited, which reported a turnover of ₹5,313.08 lakh.

What the Numbers Show

The standalone entity incurred an operating loss before tax of ₹116.03 lakh, driven by cost of materials consumed at ₹1,060.43 lakh against revenue of ₹1,095.99 lakh. This indicates thin margins in the core trading business. Conversely, the consolidated group generated an operating profit before tax of ₹44.13 lakh. The primary driver of this profitability is the subsidiary VSR Paper and Packaging Limited, which contributed significantly to the top line while the holding company struggled with standalone operational efficiency. The acquisition of Craftsmart Products Private Limited, now a wholly-owned subsidiary, added ₹136.40 lakh to consolidated revenue but incurred a net loss of ₹45.82 lakh.

Corporate Actions

The Board proposed the reappointment of M/s. M.M. Reddy & Co. as statutory auditors for a second term of three years. Remuneration is fixed at ₹2,00,000 per annum plus taxes. Mr. Suryaprakasa Rao Bommisetti seeks reappointment as an Independent Director for a five-year term effective from March 7, 2027. Mr. Bhandaram Premsai Reddy retires by rotation and offers himself for re-appointment as a Non-Executive Director.

The company increased its authorized share capital from ₹12 crore to ₹19 crore during the year. Paid-up capital rose to ₹17.97 crore following the preferential allotment of shares to acquire Craftsmart Products Private Limited. No dividend was recommended for FY26.

Bandaram Pharma Packtech has announced a revision in its subsidiary's textbook order value, adjusting it to Rs 27.71 crore from the earlier reported figure of Rs 37.44 crore. The development signals a downward recalibration of the order, representing a reduction from the originally disclosed amount.

Order Value Revision at a Glance

The following table summarizes the key details of the order value adjustment:

The revised order value of Rs 27.71 crore reflects a decrease compared to the previously announced Rs 37.44 crore. The adjustment pertains to a textbook order held by the company's subsidiary. No additional information regarding the rationale behind the revision or the identity of the counterparty has been disclosed in the available data.